Your Article Summary
See Latest ArticlesThe natural history of bladder carcinoma in situ after initial response to bacillus Calmette-Guerin immunotherapy
Urologic Oncology: Seminars and Original Investigations, 07/01/09
Gofrit ON et al. - In a trial to explore patterns of recurrence, muscle invasion, and disease-specific mortality in pts with bladder carcinoma in situ (CIS) who responded to an induction course with intravesical bacillus Calmette-Gúerin (BCG) immunotherapy, it was shown that pure and concomitant bladder CIS share similar biologic behavior. Muscle-invasive disease is expected in about 25% of BCG responders followed for long time periods and disease-specific mortality in 15%. Tumor recurrence, whether nonmuscle-invasive or muscle-invasive, follows a similar time table suggesting that these are not sequential but parallel and independent processes.
Methods- 104 pts were diagnosed with either pure (38 pts) or concomitant (66 pts) CIS.
- Pts who responded to 1 (92 pts) or 2 (12 pts) induction courses of intravesical BCG instillation were included.
- Response was determined and monitored by routine periodic bladder biopsies.
- Outcome of pts and effect of various prognostic parameters were assessed after a median follow-up of 75 mos.
- 5- and 10-yr recurrence-free survival rates were 63% and 54%, respectively.
- 5- and 10-yr muscle-invasive-free survival rates were 79% and 77%, and 5- and 10-yr disease-specific survival rates were 90.5 and 85.8%, respectively.
- Median time to recurrence, muscle invasion, and disease-specific mortality was 18, 19, and 40 mos, respectively.
- Pure and concomitant CIS were associated with a similar outcome.
- Recurrence of nonmuscle-invasive tumor did not increase the risk for muscle invasion or mortality.
Related Articles
A disproportion of TH1/TH2 cytokines with predominance of TH2, in urothelial carcinoma of bladder
Urologic Oncology: Seminars and Original Investigations, 10/26/09
Relevance Score: 68%
Incidence analyses of bladder cancer in the Nile delta region of Egypt
Cancer Epidemiology, 10/20/09
Relevance Score: 68%
Dermatomyositis and small cell carcinoma of the bladder
Canadian Family Physician, 10/14/09
Relevance Score: 68%
Diagnosis and Treatment of Bladder Cancer
American Family Physician, 10/01/09
Relevance Score: 68%
192R Allele of Paraoxanase 1 (PON1) Gene as a New Marker for Susceptibility to Bladder Cancer
Anticancer Research, 11/10/09
Relevance Score: 67%
Today in Renal/Urologic...keeping you current
Receive free subspecialty "5-minute updates" via email
Total Cystectomy Versus Bladder Preservation Therapy for Locally Invasive Bladder Cancer: Effect of Combined Therapy Using Balloon-Occluded Arterial Infusion of Anticancer Agent and Hemodialysis With Concurrent Radiation
American Journal of Clinical Oncology, 12/07/09
Udp-glucose dehydrogenase as a novel field-specific candidate biomarker of prostate cancer
International Journal of Cancer, 12/07/09
Update on novel agents in renal cell carcinoma
Expert Review of Anticancer Therapy, 12/07/09